A bladder-sparing approach for muscle-invasive bladder cancer

A bladder-sparing approach for muscle-invasive bladder cancer

VJOncology

1 year
195 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Elizabeth Plimack, MD, from Fox Chase Cancer Center, Philadelphia, PA, introduces the key trials in progress at her center, including a treatment allocation study for patients with muscle-invasive localized bladder cancer, which features a combination of cystoscopy and tumour genomics to reduce the number of patients undergoing cystectomy. In addition, Dr Plimack also highlights a trial testing the combination of nivolumab and axitinib for kidney cancer (NCT03172754). Finally, she discusses a study looking to sensitize bladder cancer patients that are refractory to PD-1 inhibiton using guadecitabine (NCT03179943).
Up Next Autoplay
Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care
Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care
Category: News
3 Views
Cancer-News 2 days
Long-Term Results from Phase 3 ALTA-1L Trial
Long-Term Results from Phase 3 ALTA-1L Trial
Category: Non-Small Cell Lung Cancer
26 Views
Cancer-News 3 days
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Category: News
2 Views
Cancer-News 3 days
Treatment-Free Survival, With and Without Toxicity
Treatment-Free Survival, With and Without Toxicity
Category: Kidney Cancer
10 Views
kidneycancer 3 days
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Category: Kidney Cancer
1 Views
kidneycancer 3 days
What's To Come in Modern Imaging Technology
What's To Come in Modern Imaging Technology
Category: Kidney Cancer
4 Views
kidneycancer 4 days
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
5 Views
Cancer-News 4 days
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
Category: Breast Cancer
6 Views
Cancer-News 4 days
Modern Imaging Technology
Modern Imaging Technology
Category: Kidney Cancer
11 Views
kidneycancer 5 days
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
Category: News
3 Views
Cancer-News 5 days